Blog

What Is the Bronchiectasis and NTM Care Center Network?

This blog post was authored by Lucinda Shore and reviewed by the Bronchiectasis and NTM Content Review and Evaluation Committee.As bronchiectasis and nontuberculous mycobacterial (NTM) lung disease become more common in the U.S., getting a quick, accurate diagnosis and expert care is very important. To help meet this need, the Bronchiectasis and NTM Association created the Bronchiectasis and NTM Care Center Network (CCN).The CCN connects people to medical centers throughout the U.S. that provide expert care and treatment, high-quality education, advice, and support for those living with bronchiectasis and NTM lung disease. The CCN gives sites one of two designations:Care Center: These centers offer a clinical research program, treat hundreds of people with bronchiectasis and NTM, and provide direct access to specialists (like dietitians or psychologists) for immediate care.Clinical Associate Center (CAC): CACs provide high-quality, expert care, but may see fewer people with both conditions, may be less involved in research, and may not have access to specialists within the center.

Press Release

Bronchiectasis and NTM Association announces collaboration with Insmed on first-in-disease observational study evaluating real-world effectiveness of brensocatib in non-CF bronchiectasis

Miami (August 12, 2026) – The Bronchiectasis and NTM Association today announced a collaboration with Insmed Incorporated, on a multicenter, prospective study designed to evaluate the real-world effectiveness, safety, and tolerability of brensocatib in adult patients with non-cystic fibrosis (non-CF) bronchiectasis.The Brensocatib Effectiveness, Safety, and Tolerability in Bronchiectasis (BEST-BE) observational study is designed to measure the incidence and frequency of pulmonary exacerbations, or episodes of sudden worsening of respiratory symptoms, in adults 18 to 85 years old with non-CF bronchiectasis observed over a two-year period.In addition, the study will track changes in participants’ health-related quality of life, and the incidence and frequency of adverse events. To deepen the evidence base for brensocatib, building on the landmark Phase 3 ASPEN study, the BEST-BE study will capture these data across a broad, diverse population of participants, including those with concurrent nontuberculous mycobacterial (NTM) lung infections and immunocompromised individuals.

Discussion

Exercise- Lace Up for Lungs Event

Are you getting prepared to Lace up for Lungs on Friday, October 9th?  Exercise is one of the best tools ⚒️ in our lung health toolbox 🧰. Below is information on this exciting event and how you can participate. https://www.copdfoundation.org/Take-Action/Get-Involved/Lace-Up-for-Lungs.aspx